quantisnow
FeedTopReportsPricing
⌘K
Live feed
12:40:00·19h
PRRelease
Regeneron Pharmaceuticals Inc. logo

Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.

REGN· Regeneron Pharmaceuticals Inc.
Health Care
Original source

Companies

  • REGN
    Regeneron Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 31UpdatePiper Sandler$875.00
  • Mar 6UpdateBarclays$923.00
  • Jan 7UpdateBofA Securities$860.00
  • Dec 3UpdateMorgan Stanley$767.00
  • Nov 24UpdateTruist$798.00
  • Nov 24UpdateHSBC Securities$255.00

Related

  • PR16h
    Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
  • PR1d
    Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
  • PR1d
    Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
  • PR2d
    Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
  • PR3d
    Regeneron Announces Investor Conference Presentations
  • PR11d
    Regeneron and Telix Announce Strategic Radiopharma Collaboration
  • PR11d
    Telix and Regeneron Announce Strategic Radiopharma Collaboration
  • PR11d
    Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022